Drug Details

General Information of the Drug (ID: DR8666)
Name
Reorafenib
Disease Colorectal cancer [ICD-11: 2B91] Investigative [1]
DrugBank ID
DB08896
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Ginsenoside      Panax ginseng     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression BIRC5  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
                    In-vitro Model Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
                    Experimental
                    Result(s)		 The synergistic inhibitory effect presented by the combination therapy was dependent on the gradient concentration and treatment time.
Target and Pathway
Target(s) Threonine protease PRSS50 (PRSS50)  Molecule Info  [3]
References
Reference 1 Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12.
Reference 2 Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression. Clin Transl Oncol. 2020 Sep;22(9):1491-1498.
Reference 3 25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression. Tumour Biol. 2016 Sep;37(9):11805-11813.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link